COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke (DUMAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04256473
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : April 7, 2020
DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution.
Information provided by (Responsible Party):
Nadinda van der Ende, Erasmus Medical Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 1, 2021
Estimated Study Completion Date : March 1, 2021